Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASFRA:PI3 +0.99%68 Days Sales Outstanding is 47.31 as of Jun. 2026, which is 44% below its 10-year median of 84.38. GuruFocus rates FRA:PI3 with a GF Score™ of 68/100 and a GF Value™ of €26.62 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, Gubra AS ranks better than 68.49% on this metric.
Gubra AS's average Accounts Receivable for the
six
months ended in Jun. 2026 was €4.38 Mil. Gubra AS's Revenue for the
six
months ended in Jun. 2026 was €16.90 Mil.
Hence, Gubra AS's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 47.31.
The historical rank and industry rank for Gubra AS's Days Sales Outstanding or its related term are showing as below:
FRA:PI3'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.63 Med: 84.38 Max: 109.9
Current: 46.3
During the past 7 years, Gubra AS's highest Days Sales Outstanding was 109.90. The lowest was 4.63. And the median was 84.38.
FRA:PI3's Days Sales Outstanding is ranked better than 68.49% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs FRA:PI3: 46.30
Gubra AS's Days Sales Outstanding
increased
from Jun. 2025 (2.54) to Jun. 2026 (47.31).
Gubra AS (FRA:PI3) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Gubra AS Days Sales Outstanding Related Terms
Gubra AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Gubra AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PI3 vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Gubra AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Gubra AS's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (FRA:PI3) has a Days Sales Outstanding of 47.31 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Gubra AS and its competitors. This is 44% below median its historical median of 84.38. Over the past decade, Gubra AS's Days Sales Outstanding has ranged from 4.63 to 109.90. According to the industry distribution chart, Gubra AS ranks #265 out of 841 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Gubra AS's Days Sales Outstanding too high?
Gubra AS's current Days Sales Outstanding of 47.31 is 44% below median its 10-year median of 84.38. Over the past 10 years, this metric has ranged from a low of 4.63 to a high of 109.90. The Biotechnology industry median Days Sales Outstanding is 68.98. Gubra AS's value of 47.31 is 31.4% below this industry median. Based on the distribution chart, Gubra AS ranks #265 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gubra AS has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #265 out of 841 companies for Days Sales Outstanding. This puts Gubra AS in the upper half of its industry. The industry median Days Sales Outstanding is 68.98. Gubra AS's value of 47.31 is 31.4% below this benchmark. Historically, Gubra AS's own Days Sales Outstanding has ranged from 4.63 to 109.90 over the past decade. While the company's 10-year median is 84.38 vs. the industry median of 68.98, Gubra AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current Days Sales Outstanding of 47.31 is 31.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Days Sales Outstanding is 47.31, which is 44% below median its own 10-year median of 84.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Significantly Overvalued. The stock's GF Value™ is €26.62, compared to a current price of €51.20 — trading 92.3% above its estimated fair value. The current Days Sales Outstanding is 47.31, which is 44% below median its 10-year median of 84.38 and 31.4% below the Biotechnology industry median of 68.98. Gubra AS's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Days Sales Outstanding is 47.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued.
The current stock price of €51.20 is trading 92.3% above its estimated GF Value™ of €26.62.
GuruFocus considers Gubra AS to be Significantly Overvalued.
Key valuation signals for FRA:PI3:
Days Sales Outstanding: 47.31 (44% below median its 10-year median of 84.38)
GF Value™: €26.62 vs. price of €51.20 (92.3% above fair value)
Industry Position: 31.4% below the Biotechnology median (#265 of 841)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
68GF Score
Get the complete analysis for FRA:PI3
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
